Skip to main content
. 2016 Jul 6;7(31):49722–49732. doi: 10.18632/oncotarget.10437

Figure 5. IKZF1 binds to the CRLF2 promoters and IKZF1 deletion results in changes of its expression in primary ALL cells.

Figure 5

(A) Comparison of CRLF2 expression in patients with or without IKZF1 deletion, presented as CRLF2/GAPDH. The detection method for Ik6 (the most common Ikaros deletion) was done as our previously reported (23). (B) CK2 inhibitor-TBB increased the IKZF1 binding to the promoters of CRLF2 in primary B-ALL(left) and T-ALL (right) cells. (C) Effect of CK2 inhibitor-TBB functioning as IKZF1 activator on expression of CRLF2 in primary B-ALL(left) and T-ALL (right) cells with TBB treatment for 2 days.**P < 0.01.